Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes

AIMS: To compare the effects of the sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor dapagliflozin on estimated (ePV) and measured plasma volume (mPV) and to characterize the effects of dapagliflozin on ePV in a broad population of patients with type 2 diabetes. MATERIALS AND METHODS: The Strauss f...

Descripción completa

Detalles Bibliográficos
Autores principales: Dekkers, Claire C. J., Sjöström, C. David, Greasley, Peter J., Cain, Valerie, Boulton, David W., Heerspink, Hiddo J. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899523/
https://www.ncbi.nlm.nih.gov/pubmed/31407856
http://dx.doi.org/10.1111/dom.13855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899523/
https://www.ncbi.nlm.nih.gov/pubmed/31407856
http://dx.doi.org/10.1111/dom.13855

Ejemplares similares